Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2014

Open Access 01-04-2014 | Research article

CD4+CD25-Foxp3+ T cells: a marker for lupus nephritis?

Authors: Michael Bonelli, Lisa Göschl, Stephan Blüml, Thomas Karonitsch, Carl-Walter Steiner, Günter Steiner, Josef S Smolen, Clemens Scheinecker

Published in: Arthritis Research & Therapy | Issue 2/2014

Login to get access

Abstract

Introduction

Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease, which can affect different organs. Increased proportions of CD4+CD25-Foxp3+ T cells have been described in SLE patients. The exact role of this cell population in SLE patients still remains unclear. We therefore analyzed this T cell subset in a large cohort of SLE patients with different organ manifestations.

Methods

Phenotypic analyses, proportions and absolute cell numbers of CD4+CD25-Foxp3+ T cells were determined by flow cytometry (FACS) in healthy controls (HC) (n = 36) and SLE patients (n = 61) with different organ manifestations. CD4+CD25-Foxp3+ T cells were correlated with clinical data, the immunosuppressive therapy and different disease activity indices. In patients with active glomerulonephritis, CD4+CD25-Foxp3+ T cells were analyzed in urine sediment samples. Time course analyses of CD4+CD25-Foxp3+ T cells were performed in patients with active disease activity before and after treatment with cyclophosphamide and prednisone.

Results

CD4+CD25-Foxp3+ T cells were significantly increased in active SLE patients and the majority expressed Helios. Detailed analysis of this patient cohort revealed increased proportions of CD4+CD25-Foxp3+ T cells in SLE patients with renal involvement. CD4+CD25-Foxp3+ T cells were also detected in urine sediment samples of patients with active glomerulonephritis and correlated with the extent of proteinuria.

Conclusion

CD4+CD25-Foxp3+ T cells resemble regulatory rather than activated T cells. Comparative analysis of CD4+CD25-Foxp3+ T cells in SLE patients revealed a significant association of this newly described cell population with active nephritis. Therefore CD4+CD25-Foxp3+ T cells might serve as an important tool to recognize and monitor SLE patients with renal involvement.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4 + CD25 high regulatory cells in human peripheral blood. J Immunol. 2001, 167: 1245-1253. 10.4049/jimmunol.167.3.1245.CrossRefPubMed Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4 + CD25 high regulatory cells in human peripheral blood. J Immunol. 2001, 167: 1245-1253. 10.4049/jimmunol.167.3.1245.CrossRefPubMed
2.
go back to reference Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T: Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med. 1985, 161: 72-87. 10.1084/jem.161.1.72.CrossRefPubMed Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T: Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med. 1985, 161: 72-87. 10.1084/jem.161.1.72.CrossRefPubMed
3.
go back to reference Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000, 12: 431-440. 10.1016/S1074-7613(00)80195-8.CrossRefPubMed Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA: B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000, 12: 431-440. 10.1016/S1074-7613(00)80195-8.CrossRefPubMed
4.
go back to reference Shevach EM, McHugh RS, Piccirillo CA, Thornton AM: Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001, 182: 58-67. 10.1034/j.1600-065X.2001.1820104.x.CrossRefPubMed Shevach EM, McHugh RS, Piccirillo CA, Thornton AM: Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev. 2001, 182: 58-67. 10.1034/j.1600-065X.2001.1820104.x.CrossRefPubMed
5.
go back to reference Suri-Payer E, Cantor H: Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun. 2001, 16: 115-123. 10.1006/jaut.2000.0473.CrossRefPubMed Suri-Payer E, Cantor H: Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4(+)CD25(+) T cells. J Autoimmun. 2001, 16: 115-123. 10.1006/jaut.2000.0473.CrossRefPubMed
6.
go back to reference Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000, 192: 295-302. 10.1084/jem.192.2.295.PubMedCentralCrossRefPubMed Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000, 192: 295-302. 10.1084/jem.192.2.295.PubMedCentralCrossRefPubMed
7.
go back to reference Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C: Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol. 2008, 20: 861-868. 10.1093/intimm/dxn044.CrossRefPubMed Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, Scheinecker C: Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol. 2008, 20: 861-868. 10.1093/intimm/dxn044.CrossRefPubMed
8.
go back to reference Bluestone JA, Tang Q, Sedwick CE: T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol. 2008, 28: 677-684. 10.1007/s10875-008-9242-z.CrossRefPubMed Bluestone JA, Tang Q, Sedwick CE: T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol. 2008, 28: 677-684. 10.1007/s10875-008-9242-z.CrossRefPubMed
9.
go back to reference Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed
10.
go back to reference Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, Huehn J, Hori S: Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity. 2012, 36: 262-275. 10.1016/j.immuni.2011.12.012.CrossRefPubMed Miyao T, Floess S, Setoguchi R, Luche H, Fehling HJ, Waldmann H, Huehn J, Hori S: Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity. 2012, 36: 262-275. 10.1016/j.immuni.2011.12.012.CrossRefPubMed
11.
go back to reference Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003, 4: 330-336. 10.1038/ni904.CrossRefPubMed Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003, 4: 330-336. 10.1038/ni904.CrossRefPubMed
12.
go back to reference Sakaguchi S: Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005, 6: 345-352.CrossRefPubMed Sakaguchi S: Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005, 6: 345-352.CrossRefPubMed
14.
go back to reference Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol. 2006, 24: 209-226. 10.1146/annurev.immunol.24.021605.090547.CrossRefPubMed Ziegler SF: FOXP3: of mice and men. Annu Rev Immunol. 2006, 24: 209-226. 10.1146/annurev.immunol.24.021605.090547.CrossRefPubMed
15.
go back to reference Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM: Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010, 184: 3433-3441. 10.4049/jimmunol.0904028.PubMedCentralCrossRefPubMed Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, Shevach EM: Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010, 184: 3433-3441. 10.4049/jimmunol.0904028.PubMedCentralCrossRefPubMed
16.
go back to reference Kim YC, Bhairavabhotla R, Yoon J, Golding A, Thornton AM, Tran DQ, Shevach EM: Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood. 2012, 119: 2810-2818. 10.1182/blood-2011-09-377895.PubMedCentralCrossRefPubMed Kim YC, Bhairavabhotla R, Yoon J, Golding A, Thornton AM, Tran DQ, Shevach EM: Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood. 2012, 119: 2810-2818. 10.1182/blood-2011-09-377895.PubMedCentralCrossRefPubMed
17.
go back to reference Golding A, Hasni S, Illei G, Shevach EM: The percentage of FoxP3 + Helios + Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2013, 65: 2898-2906. 10.1002/art.38119.PubMedCentralCrossRefPubMed Golding A, Hasni S, Illei G, Shevach EM: The percentage of FoxP3 + Helios + Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum. 2013, 65: 2898-2906. 10.1002/art.38119.PubMedCentralCrossRefPubMed
18.
go back to reference Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C: Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol. 2009, 182: 1689-1695. 10.4049/jimmunol.182.3.1689.CrossRefPubMed Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C: Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol. 2009, 182: 1689-1695. 10.4049/jimmunol.182.3.1689.CrossRefPubMed
19.
go back to reference Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE: Clinical significance of increased CD4 + CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis. 2008, 67: 1037-1040. 10.1136/ard.2007.083543.CrossRefPubMed Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE: Clinical significance of increased CD4 + CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis. 2008, 67: 1037-1040. 10.1136/ard.2007.083543.CrossRefPubMed
20.
go back to reference Yan B, Liu Y: The nature of increased circulating CD4CD25Foxp3 T cells in patients with systemic lupus erythematosus: a novel hypothesis. Open Rheumatol J. 2009, 3: 22-24. 10.2174/1874312900903010022.PubMedCentralCrossRefPubMed Yan B, Liu Y: The nature of increased circulating CD4CD25Foxp3 T cells in patients with systemic lupus erythematosus: a novel hypothesis. Open Rheumatol J. 2009, 3: 22-24. 10.2174/1874312900903010022.PubMedCentralCrossRefPubMed
21.
go back to reference Yang HX, Zhang W, Zhao LD, Li Y, Zhang FC, Tang FL, He W, Zhang X: Are CD4 + CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?. Arthritis Res Ther. 2009, 11: R153-10.1186/ar2829.PubMedCentralCrossRefPubMed Yang HX, Zhang W, Zhao LD, Li Y, Zhang FC, Tang FL, He W, Zhang X: Are CD4 + CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells?. Arthritis Res Ther. 2009, 11: R153-10.1186/ar2829.PubMedCentralCrossRefPubMed
22.
go back to reference Prado C, de Paz B, Lopez P, Gomez J, Rodriguez-Carrio J, Suarez A: Relationship between FOXP3 positive populations and cytokine production in systemic lupus erythematosus. Cytokine. 2012, 61: 90-96.CrossRefPubMed Prado C, de Paz B, Lopez P, Gomez J, Rodriguez-Carrio J, Suarez A: Relationship between FOXP3 positive populations and cytokine production in systemic lupus erythematosus. Cytokine. 2012, 61: 90-96.CrossRefPubMed
23.
go back to reference Suen JL, Li HT, Jong YJ, Chiang BL, Yen JH: Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology. 2009, 127: 196-205. 10.1111/j.1365-2567.2008.02937.x.PubMedCentralCrossRefPubMed Suen JL, Li HT, Jong YJ, Chiang BL, Yen JH: Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology. 2009, 127: 196-205. 10.1111/j.1365-2567.2008.02937.x.PubMedCentralCrossRefPubMed
24.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed
25.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640. 10.1002/art.1780350606.CrossRefPubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992, 35: 630-640. 10.1002/art.1780350606.CrossRefPubMed
26.
go back to reference Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 541-547.PubMed Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 541-547.PubMed
27.
go back to reference Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 549-554.PubMed Bencivelli W, Vitali C, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Bombardieri S: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol. 1992, 10: 549-554.PubMed
28.
go back to reference Markowitz GS, D’Agati VD: Classification of lupus nephritis. Curr Opin Nephrol Hypertens. 2009, 18: 220-225. 10.1097/MNH.0b013e328327b379.CrossRefPubMed Markowitz GS, D’Agati VD: Classification of lupus nephritis. Curr Opin Nephrol Hypertens. 2009, 18: 220-225. 10.1097/MNH.0b013e328327b379.CrossRefPubMed
29.
go back to reference Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003, 21: 273-276. 10.1016/S0896-8411(03)00121-5.CrossRefPubMed Crispin JC, Martinez A, Alcocer-Varela J: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003, 21: 273-276. 10.1016/S0896-8411(03)00121-5.CrossRefPubMed
30.
go back to reference Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN: Reduced number and function of CD4 + CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol. 2007, 601: 113-119. 10.1007/978-0-387-72005-0_12.CrossRefPubMed Lyssuk EY, Torgashina AV, Soloviev SK, Nassonov EL, Bykovskaia SN: Reduced number and function of CD4 + CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol. 2007, 601: 113-119. 10.1007/978-0-387-72005-0_12.CrossRefPubMed
31.
go back to reference Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J: Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus. 2008, 17: 289-294. 10.1177/0961203307088307.CrossRefPubMed Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J: Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus. 2008, 17: 289-294. 10.1177/0961203307088307.CrossRefPubMed
32.
go back to reference Suarez A, Lopez P, Gomez J, Gutierrez C: Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006, 65: 1512-1517. 10.1136/ard.2005.049924.PubMedCentralCrossRefPubMed Suarez A, Lopez P, Gomez J, Gutierrez C: Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis. 2006, 65: 1512-1517. 10.1136/ard.2005.049924.PubMedCentralCrossRefPubMed
33.
go back to reference Azab NA, Bassyouni IH, Emad Y, Abd El-Wahab GA, Hamdy G, Mashahit MA: CD4 + CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clinical immunology. 2008, 127: 151-157. 10.1016/j.clim.2007.12.010.CrossRefPubMed Azab NA, Bassyouni IH, Emad Y, Abd El-Wahab GA, Hamdy G, Mashahit MA: CD4 + CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clinical immunology. 2008, 127: 151-157. 10.1016/j.clim.2007.12.010.CrossRefPubMed
34.
go back to reference Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH: The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007, 37: 987-996. 10.1111/j.1365-2362.2007.01882.x.CrossRefPubMed Lin SC, Chen KH, Lin CH, Kuo CC, Ling QD, Chan CH: The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest. 2007, 37: 987-996. 10.1111/j.1365-2362.2007.01882.x.CrossRefPubMed
Metadata
Title
CD4+CD25-Foxp3+ T cells: a marker for lupus nephritis?
Authors
Michael Bonelli
Lisa Göschl
Stephan Blüml
Thomas Karonitsch
Carl-Walter Steiner
Günter Steiner
Josef S Smolen
Clemens Scheinecker
Publication date
01-04-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4553

Other articles of this Issue 2/2014

Arthritis Research & Therapy 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.